Schizophrenia News and Research

Latest Schizophrenia News and Research

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

UCLA has joined an international consortium to investigate the high rates of schizophrenia and other neuropsychiatric disorders in those who are affected with Chromosome 22q11.2 deletion syndrome, a disorder caused by the deletion of a small piece of chromosome number 22.

9 Oct 2013

Researchers study link between newborn infections and later behavior problems

Researchers exploring the link between newborn infections and later behavior and movement problems have found that inflammation in the brain keeps cells from accessing iron that they need to perform a critical role in brain development.

9 Oct 2013

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia.

9 Oct 2013

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Motivational interviewing may help specific subgroups of patients with schizophrenia to adhere to their antipsychotic medication, a study suggests.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

The Brain & Behavior Research Foundation celebrates the transformative power of neuroscience and psychiatric research to improve the lives of those with mental illness. Seven exceptional scientists will be honored at the Annual National Awards Dinner at the Pierre Hotel in New York City on Friday, October 25, 2013.

7 Oct 2013

Penn Medicine receives $12M NIHM grant for genetics study that points causes of mental illness

A major international consortium co-led by Penn Medicine has received a $12 million National Institute of Mental Health (NIHM) grant for a large-scale genetics study investigating why patients with chromosome 22q11.2 deletion syndrome have an increased risk of schizophrenia and other psychiatric disorders.

4 Oct 2013

CHOP’s 22q and You Center plays major role in brain and behavior consortium

Genetics experts from The Children's Hospital of Philadelphia (CHOP) are among the top leaders of a major international collaboration researching why patients with chromosome 22q11.2 deletion syndrome have an elevated risk of schizophrenia and other psychiatric illnesses.

4 Oct 2013

Parkinsonism predicts schizophrenia cognitive course

Parkinsonism is common in patients with first-episode psychosis and is predictive of cognitive impairment, say researchers.

3 Oct 2013

Adolescent psychotic experiences lack uniformity

Psychotic experiences in adolescence appear to be quite distinct and vary widely from individual to individual, study findings indicate.

3 Oct 2013

Community programs promote independent living among people with serious mental illness

A new analysis by Oregon State University researchers of California's mental health system finds that comprehensive, community-based mental health programs are helping people with serious mental illness transition to independent living.

3 Oct 2013

NIMH Awards Optivia $1.8M CNS Drug Development

...

2 Oct 2013

Maternal smoking during pregnancy associated with twofold increased risk of BD in offspring

A study published today in the American Journal of Psychiatry suggests an association between smoking during pregnancy and increased risk for developing bipolar disorder in adult children.

2 Oct 2013

Carbonyl stress suggests strategy for treatment-resistant schizophrenia

Patients with schizophrenia who have enhanced carbonyl stress have clinical features associated with treatment resistance, say researchers.

1 Oct 2013

Three UC Irvine scientists receive prestigious 2013 NIH New Innovator Awards

UC Irvine scientists Aaron Esser-Kahn, Sunil Gandhi and Ali Mortazavi have been named recipients of the prestigious 2013 National Institutes of Health Director's New Innovator Awards.

1 Oct 2013

Psychosomatics study shows prevalence of nightmares disorder in psychiatric patients

A study published in the current issue of psychotherapy and psychosomatics provides data concerned with the prevalence of nightmares disorder in psychiatric patients.

1 Oct 2013

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Omeros Corporation announced that OMS824, its phosphodiesterase 10 inhibitor, has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of Huntington's disease.

30 Sep 2013

Schizophrenia News and Research

Latest Schizophrenia News and Research

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

Researchers study link between newborn infections and later behavior problems

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

‘Targeted’ motivational interviewing may improve antipsychotic adherence

Brain & Behavior Research Foundation to hold research symposium on mental health

NAC amino acid may offer new treatment options for psychiatric disorders

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

Penn Medicine receives $12M NIHM grant for genetics study that points causes of mental illness

CHOP’s 22q and You Center plays major role in brain and behavior consortium

Parkinsonism predicts schizophrenia cognitive course

Adolescent psychotic experiences lack uniformity

Community programs promote independent living among people with serious mental illness

NIMH Awards Optivia $1.8M CNS Drug Development

Maternal smoking during pregnancy associated with twofold increased risk of BD in offspring

Carbonyl stress suggests strategy for treatment-resistant schizophrenia

Three UC Irvine scientists receive prestigious 2013 NIH New Innovator Awards

Psychosomatics study shows prevalence of nightmares disorder in psychiatric patients

Omeros' OMS824 gets FDA orphan drug designation for treatment of Huntington's disease

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Schizophrenia News and Research

Latest Schizophrenia News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in